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ABSTRACT
Introduction Adequate nutrition during pregnancy is 
crucial to both mother and child. Maternal malnutrition can 
be the cause of stillbirth or lead to poor birth outcomes 
such as preterm delivery and small- for- gestational- 
age newborns. There is a probable positive effect of 
providing pregnant women a balanced energy- protein 
(BEP) food supplement, but more evidence is needed. The 
MIcronutriments pour la SAnté de la Mère et de l’Enfant 
(MISAME) III project aims to improve birth outcomes 
and infant growth by testing a BEP supplement during 
pregnancy and lactation in rural Burkina Faso. This paper 
describes the study protocol.
Methods and analysis MISAME- III is a four- arm 
individually randomised efficacy trial implemented in 
six rural health centre catchments areas in the district 
of Houndé. Eligible pregnant women, aged between 15 
and 40 years old and living in the study areas, will be 
enrolled. Women will be randomly assigned to one of 
the four study groups: (1) prenatal intervention only, (2) 
postnatal intervention only, (3) prenatal and postnatal 
intervention or (4) no prenatal or postnatal intervention. 
The intervention group will receive the BEP supplement 
and iron/folic acid (IFA) tablets, while the control group will 
only receive the IFA tablets following the national health 
protocol. Consumption will be supervised by trained village 
women on a daily basis by means of home visits. The 
primary outcomes are small- for- gestational age at birth 
and length- for- age z- score at 6 months of age. Secondary 
outcomes will be measured at birth and during the first 
6 months of the infants’ life. Women will be enrolled from 
October 2019 until the total sample size is reached.
Ethics and dissemination MISAME- III has been reviewed 
and approved by the University Hospital of Ghent and the 
ethics committee of Centre Muraz, Burkina Faso. Informed 
consent will be obtained. Results will be published in 
relevant journals and shared with other researchers and 
public health institutions.
Trial registration number NCT03533712.
INTRODUCTION
Pregnancy is a challenging period in the 
life of many women in low- income and 
middle- income countries (LMICs). Maternal 
mortality remains high, and many neonates 
suffer from premature delivery and/or intra-
uterine growth retardation, both in length 
and in weight accumulation.1 An indicator 
to measure neonatal growth is small- for- 
gestational age (SGA). SGA is defined as a 
birth weight below the 10th percentile of a 
standard optimal reference population for a 
given gestational age and sex.2 SGA is often 
caused by growth restriction in the womb 
and has been associated with neonatal and 
postneonatal mortality.2 It has also been 
linked to an increased risk of morbidity later 
Strengths and limitations of this study
 ► This trial will help to fill the evidence gap on the ef-
fect of balanced energy- protein (BEP) supplements 
in pregnant and lactating women on birth outcomes 
and infant growth.
 ► Formative research to select the most suitable BEP 
supplement ensured that the selected BEP is well 
accepted by the study population.
 ► The daily intake of BEP supplements and iron/folic 
acid tablets during pregnancy and lactation will be 
directly observed by study workers.
 ► This study will assess the impact of factorial com-
binations of prenatal and postnatal BEP on child 
growth to elucidate the relative importance of BEP 
during pregnancy and/or early lactation.
 ► Blinding of study participants and staff members will 
not be possible, as the supplements are identifiable.
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in life, especially non- communicable diseases.3 SGA 
affected 23.3 million term children in LMICs in 2012.4 
Adequate nutrition during pregnancy is crucial for 
optimal maternal and newborn health,5 6 and maternal 
malnutrition has been associated with fetal growth restric-
tion.7 An adequate dietary balance is necessary to ensure 
sufficient energy intake for adequate growth of the fetus.8 
Unfortunately, maternal undernutrition remains a public 
health challenge in regions across sub- Saharan Africa and 
Asia.9 10
Several types of food supplements have been devel-
oped and evaluated over the past years. A positive effect 
of multiple micronutrient supplements (MMS) during 
pregnancy on birth outcomes has been found in previous 
studies.11 Keats et al11 concluded in their review that MMS 
during pregnancy gave a probable reduction in SGA and 
preterm births and can thus be used for future guidance. 
According to a multicountry randomised controlled 
trial (RCT) done in LMICs, a positive effect of lipid- 
based nutrient supplements on fetal growth- related birth 
outcomes can be seen when starting supplementation 
before conception or during the first trimester.12 More-
over, the latest evidence indicates a possible positive effect 
of providing pregnant women a balanced energyprotein 
(BEP) food supplement.5 13–15 In line with that evidence, 
the 2016 WHO’s antenatal care guidelines state that 
pregnant women in undernourished populations should 
receive, depending on the context, BEP supplements 
to reduce the risk of stillbirth and SGA.6 Researchers, 
however, still highlight the limited amount of evidence 
and a need to evaluate the effect of balanced supple-
ments on birth outcomes, such as SGA.5 13 Experimental 
trials of high- quality and large sample sizes, especially in 
undernourished pregnant women, are thus needed.13 
Following this recommendation, compositional guidance 
for a ready- to- use food supplement for pregnant women 
was developed by the Bill and Melinda Gates Foundation 
(BMGF) in 2016.16
Two previous projects, MIcronutriments pour la SAnté 
de la Mère et de l’Enfant (MISAME) I and II, conducted 
in Burkina Faso, investigated the effect of supplementa-
tion during pregnancy and the effect on birth outcomes 
in infants.17 18 MISAME- I compared the effect of the 
UNICEF/WHO/UNU international multiple micro-
nutrient preparation (UNIMMAP) with the effect of 
iron/folic acid (IFA) alone on fetal growth in a double- 
blind RCT and concluded that UNIMMAP modestly 
but significantly increased fetal growth.17 The second 
study (MISAME- II) assessed the effect of a lipid- based 
nutrient supplement fortified with UNIMMAP compared 
with a UNIMMAP tablet during pregnancy in an open- 
label, individually randomised controlled trial on birth 
anthropometry. It was found that combining energy with 
micronutrients during the prenatal phase led to larger 
birth lengths.18 Since MISAME- II used the UNIMMAP 
as a control, a complete assessment of the impact of 
the fortified lipid- based UNIMMAP was not possible. 
Therefore, MISAME- III will study the effect of a BEP 
supplementation, compared with a control group, and 
extend the supplementation postnatally to investigate the 
net contribution of prenatal and postnatal BEP supple-
mentation on child linear growth up to 6 months of age.
In summary, the MISAME- III study hypothesises that: 
(1) providing women with a BEP supplement during 
pregnancy will decrease the incidence of SGA compared 
with the control group; and (2) providing them with a 
BEP supplement during the postnatal period will increase 
children’s length by the age of 6 months compared with 
the control group.
METHODS
This protocol has been developed in accordance with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials guidelines (online supplemental file 1).
MISAME-III study design
The MISAME- III project is an individually randomised 2×2 
factorial efficacy trial aiming to improve birth outcomes 
and infant growth in rural Burkina Faso by testing a BEP 
supplement during pregnancy and lactation (figure 1). 
At inclusion, pregnant women will be individually and 
randomly allocated to a prenatal intervention or control 
group and a postnatal intervention or control group. The 
intervention group will receive a daily BEP supplement to 
be consumed under supervision for the duration of preg-
nancy/lactation. Both intervention and control groups 
will receive the standard IFA tablet through the national 
antenatal care. In addition to the main trial, we propose 
a number of substudies to test specific hypotheses in a 
subsample of pregnant/lactating women and children. 
MISAME- III began with a formative study to identify the 
preferred product type for the provision of a fortified 
BEP supplement during the RCT.
Figure 1 Study design of the randomised controlled trial.
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Study setting
The study will be conducted in the district of Houndé 
in Burkina Faso, a landlocked country situated in West- 
Africa; similar to the previous MISAME studies, Burkina 
Faso has an infant mortality rate of 53 per 1.000 live 
births,19 with an estimated Low Birth Weight (LBW) prev-
alence at 14% in 2013.20 The prevalence of SGA has been 
estimated to be between 32.2% and 41.6% in the district 
of Houndé.17 The Demographic and Health Survey of 
2010 reported that 16% of women had a body mass index 
(BMI) below 18.5 kg/m2, which indicates the presence 
of chronic energy deficiencies in the zone.21 The highest 
prevalence can be found in the Eastern region, where 
31% of women have a BMI lower than 18.5 kg/m², that is, 
low BMI.22 Moreover, in particular, adolescent Burkinabèe 
girls between the age of 15 and 19 years have a low BMI, 
with an estimated prevalence of 23%.23 Micronutrient 
deficiencies also remain a major problem in both infants 
and women of reproductive age in the country.23 24
The climate of the country is Sudano- Sahelian, with 
a dry season from October to March/April and a rainy 
season from May until September/October. The diet is 
essentially cereal based25 with maize as the main staple 
food.26
MISAME- III will be conducted in the same health 
district where the two previous MISAME studies were 
organised. The study villages are concentrated around six 
health centres, which are within an accessible range from 
the district hospital. A list of all study sites can be found 
on: www. misame3. ugent. be
Study population and recruitment
Women living in the study villages and aged between 15 
and 40 years will be identified through a census. The 
villages were selected based on their accessibility and 
distance to the nearest health centre, number of facility- 
based deliveries per year and their agricultural model as 
some households tend to reside on their fields during 
the harvest season. Trained village women (femme 
accompagnante (FA)), selected in collaboration with the 
community leaders, will visit the households every 5 weeks 
to ask about women’s menstruation. In case of amenor-
rhoea, women will be sent to the nearest health centre 
for a pregnancy test and a first antenatal consultation by 
our project midwife when tested positive. An ultrasound 
examination will be completed soon after inclusion by the 
project medical doctor to assess gestational age. A base-
line interview will also be done by the project interviewers 
to assess the household members’ characteristics, house-
hold properties, water sanitation and hygiene (WASH) 
and household food security.
Inclusion criteria:
 ► Women between 15 and 40 years old at study inclusion.
 ► Confirmed pregnancy by a pregnancy test and 
ultrasound.
 ► Women who signed the informed consent form.
Exclusion criteria:
 ► Pregnancies >20 weeks of gestational age.
 ► Women planning on leaving the area during their 
pregnancy.
 ► Women planning on delivering outside the study area.
 ► Women who are allergic to peanuts.
 ► Women with multifetal gestations (exclusion from 
analysis).
FAs will be informed by the project midwife when a 
participant has been included. FAs will visit pregnant 
women on a daily basis to distribute the BEP supplement 
and/or IFA tablet and to supervise consumption. During 
the postnatal period, FAs will distribute the supplements 
and IFA tablets to the intervention group on a daily basis 
until 6 weeks after birth. From that moment onwards, 
they will receive a week’s worth of BEP supplements. The 
postnatal control group will receive the IFA tablets on a 
daily basis during the first 6 weeks after birth, and partic-
ipants will thereafter be visited once a week (without any 
supplementation) to minimise the effect of home visits. 
The FA will inform women on the supplement’s func-
tion, the importance of antenatal visits during pregnancy, 
maintaining a healthy diversified diet, the importance of 
delivering at a health facility, the importance of exclusive 
breast feeding and the introduction of complementary 
foods at the age of 6 months. Throughout the study, the 
FAs will be supervised by project interviewers. Supervi-
sion visits will be conducted using Lot Quality Assurance 
Sampling schemes and empty sachet counts to ensure 
that study participant are visited according to the project 
protocol.
Manufacturing of 12 fortified BEP supplements and the 
formative study
Twelve fortified BEP supplements were pretested before 
the start of the RCT during a formative research phase. 
Several food manufacturing companies were invited to 
produce ready- to- use BEP supplements following the 
compositional guidelines proposed during an expert 
meeting hosted by the BMGF16 in September 2016 
(table 1). The BEP supplements had to be: (1) ready to 
consume, (2) not need a cold chain and (3) microbiolog-
ically stable.
Seven out of 12 supplements were characterised as sweet 
and five as savoury. Products were produced in different 
forms, including a biscuit, pillow, wafer, bar, paste, instant 
drink and soup.
In a first screening step of the formative study, the two 
most preferred BEP supplements were identified by using 
a combined evaluation approach consisting of a single 
meal test, sensory evaluation and focus group discus-
sions, in a convenience sample of 40 pregnant women. 
In a next step, we compared the acceptability of the two 
preselected BEP supplements using a 10- week home- 
feeding study, with 80 pregnant women, to select to most 
preferred product for the RCT. We refer to both papers 
for detailed information.27 28
Study intervention
At inclusion, pregnant women will be randomly allocated 
to four different study groups: (1) prenatal intervention 
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only, (2) postnatal intervention only, (3) prenatal and 
postnatal intervention or (4) no prenatal and no post-
natal intervention. Prenatal and postnatal supplementa-
tion will start right after inclusion and birth, respectively. 
The prenatal intervention group will receive the BEP 
supplement and IFA, while the control group will receive 
IFA tablets alone. The IFA tablets contain 65 mg iron and 
0.4 mg folic acid. The postnatal intervention group will 
receive the BEP supplement for 6 months in combination 
with the IFA tablets for 6 weeks following the national 
protocol of Burkina Faso; the control group will receive 
IFA alone for 6 weeks.
Allocation/randomisation
We will apply a stratified permuted block randomisation 
schedule to allocate women to the prenatal intervention 
or control group and in a next step to allocate women 
to a postnatal intervention and control group. Per health 
centre (ie, stratum), women will be individually randomly 
in permuted blocks of 8 so that, per block, equal numbers 
are obtained in the prenatal intervention (n=4) and 
control (n=4) group and equal numbers are also obtained 
in the postnatal intervention (n=4) and control (n=4) 
group. The double random sequence will be generated 
before the start of the study using Stata V.15.1 (Statacorp, 
Texas, USA) by an external research analyst. The alloca-
tion group will be coded with two letters (A or B for the 
prenatal and Y or Z for the postnatal study group) and 
placed in a sequentially numbered sealed opaque enve-
lopes by project employees, not in direct contact with 
participants. At study enrolment, the project midwife will 
draw the next sealed envelope and allocate the partici-
pant to the study group defined by the letter code in the 
envelope. Blinding of participants and community- based 
project workers will not be possible since the supplements 
are identifiable. Field staff responsible for measuring 
primary and secondary study outcomes are not directly 
involved in the daily supplementation of the study partic-
ipants and can therefore be considered to be partially 
blinded.
Outcomes
Primary outcomes of the RCT
The trial has two primary study outcomes that will be used 
to assess the impact of the prenatal and the postnatal 
intervention, respectively:
 ► Incidence of SGA, defined as birth weight <10th 
centile of the Intergrowth 21st reference.29
 ► Length- for- age z- score (LAZ) calculated using the 
WHO 2006 growth reference at 6 months of age.30
Secondary outcomes of the RCT
A list of the trial’s secondary outcomes can be found in 
table 2.
Birth weight measurements will be defined using the 
Intergrowth 21st reference,29 and child anthropometry 
will be defined using the Child Growth Standards devel-
oped by the WHO.30
Outcomes of the substudies
Substudy 1: impact of the intervention on neonatal and 
maternal body composition 2–3 weeks after delivery.
Body composition will be determined in mother–
child dyads by deuterium dilution and analysis of saliva 
by a Fourier Transform Infrared reader (Agilent FTIR 
4500 series). The substudy will also assess if early gesta-
tion maternal BMI (defined as body weight in kilograms 
divided by the square of height in metres) modifies the 
intervention’s effect on neonatal body composition.
Substudy 2: impact of the intervention on dietary 
intake.
A dietary assessment study will be conducted, using 
a 24- hour dietary recall in a subsample of women. This 
substudy will enable us to assess possible substitution of 
the prenatal diet by the BEP supplement.
Substudy 3: impact of the intervention on breastmilk.
Breastmilk samples will be taken in the four study 
groups to compare the composition and to analyse the 
interaction between the supplementation periods.
Sample size
With an SGA prevalence of 32% and an anticipated 
decrease of 7%, a sample of 652 subjects per prenatal arm 
is required with α=0.05 and β=0.2.26 To accommodate 
for possible losses, the number of subjects per arm was 
increased to 888 (total subjects: 1776). Possible losses are 
based on previous MISAME studies where the prevalence 
Table 1 The compositional guidelines for macronutrients 
and micronutrients
Nutrition 
component Target per serving
Total energy 250–500 kcal per serving.
Fat content 10%–60% of energy intake.
Protein content 16 g (14–18 g) with a digestible 
indispensable amino acid score of ≥0.9.
Carbohydrates Between 45 g and 32 g per 100 g (added 
sucrose between 20 g and 10 g per 100 g).
Trans fats <1% of energy intake.
Fatty acid (Optional): min of 1.3 g of n-3 or 
300 mg docosahexaenoic acid 
(DHA)+eicosapentaenoic acid (of which 
200 mg DHA) to achieve a healthy n-6: ratio 
of the supplement of 5:1.
Micronutrients Vitamin A, D, E, K, B1 (thiamin), B2 
(riboflavin), B3 (niacin), B6 (pyridoxine), B9 
(folate), B12 and C; minerals: iron, zinc, 
iodine, calcium, phosphorous, copper and 
selenium.
Optionally Pantothenic acid, manganese, potassium, 
biotin and choline will be included.
  The final composition of the product will be 
determined by the selected product as the 
manufacturing process will influence the 
macronutrient composition.
 on M









pen: first published as 10.1136/bm





5Vanslambrouck K, et al. BMJ Open 2021;11:e038393. doi:10.1136/bmjopen-2020-038393
Open access
was ~26 % due to a combination of miscarriage, still-
births, multifetal pregnancies, outmigrants, maternal 
deaths and incomplete data.18 For the analysis of an 
effect of the postnatal intervention on LAZ at 6 months 
of age, the minimally detectable effect depends on the 
presence or absence of an interaction effect between the 
prenatal and postnatal intervention. In the absence of a 
statistically significant interaction between prenatal and 
postnatal intervention, at sample size of 588 children 
per postnatal study arm would allow us to detect a differ-
ence of 0.18 Z- score (SD=1.1) based on a cross- sectional 
survey conducted in the Gourcy health district in Burkina 
Faso,31 between study arms with α=0.05 and β=0.20. This 
implies that if ~1400 singleton live births are available, 
we allow for a maximum loss to follow- up of 16%. In the 
presence of a statistically significant interaction between 
prenatal and postnatal intervention, a total sample size of 
1176 represents 294 children per factorial combination 
of the prenatal and postnatal study group (four groups 
in total). A subgroup size of 294 would allow us to detect 
a difference in LAZ at 6 months of age of 0.28 assuming 
an SD of 1.1, α=0.025 (Bonferroni correction for two 
primary endpoints analyses) and β=0.20.
Data collection
Anthropometric and clinical procedures
At enrolment, anthropometric measurements from all 
women will be taken. Gestational age will be determined 
during an ultrasound consultation by measuring crown- 
rump length (7–13 weeks) or by calculating the mean of 
three to four measurements: biparietal diameter, head 
circumference, abdominal circumference and femur 
length (12–26 weeks).32
During pregnancy, clinical follow- up will consist of 
antenatal visits following the national guidelines.
At birth, anthropometric measurements of all neonates 
will be assessed in duplicate within the first 72 hours 
of life (in practice, the aim is to measure within the 24 
hours of life). After birth, mother and child will visit the 
healthcare centres monthly for a follow- up on clinical, 
Table 2 Secondary outcomes of the RCT on maternal, newborn and child level
Maternal outcomes Newborn Child
Total and trimester- specific prenatal 
weight gain and gestational weight 
change.
Birth weight (measured within 72 hours after 
birth).
Weight- for- age Z- score at 6 months of 
age (WAZ) (and 9 and 12 months on a 
subsample).
Probable and possible maternal postnatal 
depression at 2 and 6 months of child age.
Birth length (measured within 72 hours after 
birth).
Weight- for- length Z- score at 6 months 
of age (WLZ) (and 9 and 12 months on a 
subsample).
Maternal anaemia at the third antenatal 
consultation.
Ponderal or Rohrer’s index at birth. Stunting at 6 months of age.
Women’s mean and minimum dietary 
diversity score (measured twice weekly).
Gestational age at delivery. Wasting at 6 months of age.
  Large- for- gestational age. Underweight at 6 months of age.
  Chest circumference (measured within 72 
hours after birth).
Duration of exclusive breastfeeding during 
the first 6 months of age.
  Head circumference (measured within 72 
hours after birth).
Incidence of child wasting over first 
6 months of life.
  Arm circumference (measured within 72 hours 
after birth).
Weight gain over first 6 months of life.
  Incidence of preterm birth. Child mortality (between birth and 
6 months of age).
  Fetal loss. Monthly change in LAZ over first 6 months 
of life.
  Stillbirths. Monthly change in WLZ over first 6 months 
of life.
    Monthly change in WAZ over first 6 months 
of life.
    Monthly change in head circumference 
over first 6 months of life.
    Child morbidity symptoms over first 
6 months of life.
    Anaemia at 6 months of age.
    Haemoglobin concentration at 6 months 
of age.
LAZ, length- for- age z- score; RCT, randomised controlled trial.
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Table 3 Participant timeline schedule of enrolment, interventions, assessment and visits
Enrolment Allocation
Postallocation















































































Birth weight (kg) ×












× × × × × × × × ×
Morbidity × × × × × ×
Mortality × × × × × × ×
Weight (kg) and 
height (cm)
× × × × × × × ×
Continued
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anthropometric and child morbidity measures (signs 
including fever, vomiting, diarrhoea, cough, difficulty 
breathing and running nose). A subsample will be 
measured at the healthcare centres or at home by the 
project interviewers to collect postnatal data at months 
9 and 12.
Haemoglobin concentrations will be measured in 
women at enrolment and during the third antenatal care 
visit. This will be conducted at 6 months of age among 
children.
Baseline questionnaires
Prenatal and postnatal maternal depression will be 
assessed using the standardised Edinburgh Postnatal 
Depression Scale questionnaire consisting of 10 ques-
tions.33 Project midwives will be trained for this, and the 
questionnaire will be asked at inclusion and at months 
2 and 6 after birth. Socioeconomic and demographic 
information from all participants will be collected once 
included. Trained project interviewers will ask questions 
on household members’ characteristics, household prop-
erties, WASH environment and household food security.34 
The women’s dietary diversity score will be measured in 
all participating women by the FA during the home visits. 
This will be enumerated twice a week per participant 
using the Women’s Dietary Diversity Score with 11 food 
groups.35
Table 3 shows the overview of the time schedule and 
measurements of the trial.
Quality of all study data will be insured by a thorough 
training of all field staff. Procedures to handle data collec-
tion tools (questionnaires, anthropometric and clinical 
measurement material, and laboratory procedures) will 
be pretested in the field during a dry- run of ±3 months. 
Anthropometric measurement standardisations of the 
field staff will be repeated bimonthly throughout the trial. 
Anthropometric measurements will be taken in duplicate. 
Newborns will be measured within 72 hours after birth 
(preferably within the 24 hours), and all weighing scales 
and HemoCue 201+ devices will undergo weekly quality 
control. A WhatsApp group will be set up where problems 
can be communicated and solved quickly.
All data collection forms of the trial can be found on: 
www. misame3. ugent. be
Women will be designated as lost to follow- up if they 
move from the study area or withdraw their participation. 
Reasons for discontinuation will be recorded.
Women will be enrolled in the study from October 2019 
until the total sample size has been reached.
Data management and analysis
FAs will use smartphones with computer- assisted person 
interviewing programmed in CSPRO (version 7.3.1) 
to collect data during household visits. The study data 
collected by the project medical doctor, project midwives 
and interviewers will be done by Survey Solutions data 
entry software (V.19.12.6) on tablets. This data will be 
uploaded to a central server on a weekly basis. All ques-
tionnaires were programmed and have been tested on 
the Survey Solutions Designer website and include valida-
tion codes to promote the quality of the data entry in the 
field. Assignments will be sent once a week to the tablets 
of the field team, and preloaded data collected at an 
earlier contact moment will be used to lower the amount 
of incorrect data. Paper forms will also be available on the 
field as a backup.
Further data quality checks will be conducted in Stata 
V.14.2 (Statacorp, Texas, USA). Missing or inconsistent 
data outliers will be sent back to the field for revision.
Statistical analysis
We refer to the Statistical Analysis Plan of the trial ‘Statis-
tical analysis plan: Impact of a prenatal and postnatal balanced 
energy- protein supplement on birth size and postnatal child 
growth in Burkina Faso’ published on: www. misame3. ugent. 
be
Data monitoring
Data monitoring and auditing
The Data and Safety Monitoring Board is an independent 
multidisciplinary group whose members are not involved 
in the trial. The board consists of a Belgian endocrinolo-
gist, a Belgian paediatrician, a Burkinabè paediatrician, a 
Belgian gynaecologist and a Belgian ethicist.
Enrolment Allocation
Postallocation
































*The IFA tablets will be given during the first 6 weeks after birth in the postnatal intervention group, according to the national health protocol.
†Only maternal weight will be taken at birth.
‡In a subsample at months 9 and 12.
BEP, balanced energy–protein; IFA, iron/folic acid.
Table 3 Continued
 on M









pen: first published as 10.1136/bm





8 Vanslambrouck K, et al. BMJ Open 2021;11:e038393. doi:10.1136/bmjopen-2020-038393
Open access 
Serious adverse events (SAEs)
FAs will be trained to recognise health issues and will 
actively refer those participants to see the project midwife 
in the primary health facilities or Centre de Santé et 
Promotion Sociale (CSPS) in the event they occur. All 
SAEs will be recorded on a case- by- case basis, and verbal 
autopsies will be conducted for maternal, neonatal and 
infant deaths by the field medical doctor.
ETHICS AND DISSEMINATION
Ethics approval and consent to participate
MISAME- III has been reviewed and approved by the 
University Hospital of Ghent University (B670201734334) 
and the Burkinabe ethics (N°2018–22/MS/SG/CM/CEI) 
committee. Important protocol changes will be noted on 
ClinicalTrials. gov. When eligible women meet the inclusion 
criteria, project midwives will explain the background and 
procedure of the complete trial. Written informed consent 
or assent will be asked from the participating women. In case 
of illiteracy, a thumb print will be asked and witnessed by the 
recruiting investigator and one extra witness. Participants will 
be told that all data collected during the trial is confidential 
and that they are allowed to withdraw at any time. A copy 
of the informed consent and assent can be found on www. 
misame3. ugent. be and as supplementary file (online supple-
mental file 2).
Patient and public involvement
MISAME- III has been well accepted by the community, 
because of the previous positive experiences they had 
with the MISAME- I and II studies. Through the forma-
tive study, women were involved in the choice of BEP 
supplement. Workshops will be planned at the end of the 
study in order to communicate the study results to the 
community.
Ancillary care
The MISAME- III project will pay for ancillary care when 
participants have health issues and in case the costs are 
not covered by the national healthcare programme. 
Participants suffering harm due to their trial participa-
tion will be covered.
Confidentiality
A data management plan has been put in place to address 
concerns regarding the General Data Protection Regu-
lation rules. During the trial, the data files containing 
personal identifying information will be stored on the 
Survey Solutions server. Only the principal investigators 
and the project coordinators will be able to access those 
files.
Dissemination plan
On completion of the trial, all anonymised study 
data will be available on request. Final results will 
be communicated to the participants, the Burkinabè 
Ministry of health, the field staff, the BMGF, Ghent 
University researchers and students, AFRICSanté, 
healthcare professionals and other relevant interna-
tional public institutions. Papers on the study results 
will be published in peer- reviewed journals and will 
be available on the project website. All investiga-
tors contributing to the realisation of the project 
and publication of results will be included as an 
author. Other contributors such as the participants, 
FA and field staff members will be mentioned in the 
acknowledgements.
MISAME- III has been well accepted by the community, 
because of the previous positive experiences they had 
with the MISAME- I and II studies. Through the forma-
tive study, women were involved in the choice of BEP 
supplement. Workshops will be planned at the end of the 
study in order to communicate the study results to the 
community.
DISCUSSION
In this paper, the protocol of an individually 
randomised four- arm efficacy trial in rural Burkina 
Faso has been described in which pregnant and 
lactating women in the intervention group will 
receive a BEP supplement together with IFA tablets. 
The control group will only receive the standard IFA 
treatment.
The key features of the present trial are, first, the inclu-
sion of a formative study for a better understanding of 
which type of supplement is preferred, what taste is most 
acceptable and which factors affect adherence in the 
study population. Second, the supplementation will be 
given during pregnancy and during the first 6 months 
after birth. This will give us the opportunity to assess the 
specific value of postnatal supplementation on several 
outcomes. Third, the observed daily intake of interven-
tion and control supplements is a key feature to ensure 
compliance and to avoid sharing of the supplements 
with other household members. Fourth, MISAME- III has 
the advantage of being the third trial of its kind in the 
study area. This presents an opportunity to anticipate the 
issues that arose in previous trials. For instance, women in 
specific villages tended to leave their homes for a longer 
period to go work on the fields outside the village. This 
posed problems in the continuation of the supplemen-
tation in the past and will be taken into consideration 
during MISAME- III. Fourth, four substudies are nested 
in the main trial that will provide insight into the mech-
anism by which prenatal BEP supplementation affects 
birth and infant outcomes. And last, similar studies are 
being conducted in other countries, allowing for compar-
ison between results from different contexts.
The MISAME- III study will provide evidence on the 
impact of BEP supplements on birth and infant size using 
a rigorous study design. The study results will further 
strengthen and refine WHO’s recommendation on the 
use of context- specific BEP supplementation during preg-
nancy and lactation.
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